newsfilter
← Latest News
GlobeNewswire·

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025